Mission Pharmacal Company

Mission Bend, TX, United States

Mission Pharmacal Company

Mission Bend, TX, United States
SEARCH FILTERS
Time filter
Source Type

SAN ANTONIO, Aug. 01, 2017 (GLOBE NEWSWIRE) -- Mission Pharmacal Company (“Mission”) announced today that its President of Commercial Operations, Terry Herring, and Senior Vice President of Corporate Marketing, Natalie Sirjuesingh, were honored in the 2017 July/August issue of PharmaVOICE magazine for their contributions to the life sciences industry. Alamo Pharma Services (“Alamo”) Chief Operating Officer Peter Marchesini was also honored in the issue for his work with Alamo, a member of the Mission Family of Companies. Sirjuesingh and Marchesini were named to the 2017 PharmaVOICE 100 annual list of the 100 most inspiring people working in the life sciences industry. The PharmaVOICE 100 honor recognizes leaders in the industry who have inspired others through their innovative and strategic contributions and effective leadership style. According to PharmaVOICE, these elite individuals are the driving force in the life sciences industry. Herring received the Red Jacket Award, a prestigious annual distinction created by PharmaVOICE to honor individuals who are “the best of the best,” those who have raised the bar in terms of what being an inspired leader means. To even be nominated for this distinction, individuals must have been recipients of the PharmaVOICE 100 recognition multiple times. Having three recipients this year brings the Mission Family of Companies’ total to five executives honored in the past three years. The previous two recipients were: Herring, named to PharmaVOICE 100 in 2007 and 2008, received the Red Jacket Award this year for his proven track record of being a visionary and his aptitude for devising innovative commercial solutions, attributes that allow him to bring tremendous value to the marketplace. In particular, Herring applied his strategic thinking, immense industry knowledge, and effective leadership style to help implement an innovative business strategy that led to the Mission Family of Companies, a collection of wholly-owned subsidiaries that have allowed Mission to streamline and expand its offerings. As a leader, Herring inspires and challenges others to think differently and always makes a point to engage with his employees, inspiring them to succeed. Committed to giving back to the community, Herring serves on the board of directors for Bridging the Gap Africa, a nonprofit organization that builds footbridges across rivers in Kenya to provide locals with safe crossings and access to healthcare, education and economic opportunity. First-time recipient of the honor, Sirjuesingh was named to PharmaVOICE 100 for being an extraordinary marketing executive and inspiring leader. During the transformation of the Mission Family of Companies, Sirjuesingh championed positive change on the marketing side. For example, she helped strategically link Mission with the March of Dimes Foundation®, the leading nonprofit organization for pregnancy and baby health, and continues to maintain this relationship. The outcome has been a fruitful, now eight-year relationship for both organizations. Those who work with Sirjuesingh praise her for being a mentor and an excellent role model to those around her. Her encouragement of new ideas, compassionate demeanor, and ability to produce results, no matter the obstacle, make her a leader people want to follow. Marchesini utilizes his more than 25 years of pharmaceutical industry experience to lead Alamo in offering pharmaceutical and biotech company clients an innovative and thoughtful approach to deploying high impact sales teams. The company’s turnkey solutions include service offerings ranging from recruiting and hiring to training and ongoing operational support of sales teams. Marchesini’s expertise is further enhanced by his role on the faculty at Rutgers Business School, where he co-teaches the course Managing the Pharmaceutical Sales Force, a core course of the Pharmaceutical MBA program. “Mission has always been committed to fulfilling customer and patient needs. That’s why we made the decision to expand our product and service offerings and form the Mission Family of Companies,” says Walsdorf, Jr. “Such a task required a true team effort, and Terry Herring, Natalie Sirjuesingh, and Pete Marchesini have all been key drivers. Beyond Terry’s persistent vision, Natalie’s clear focus, and Pete’s drive to make Alamo a success, each are respected leaders. Terry inspires and builds up team members to always think and act in an innovative manner, Natalie’s authentic compassion is contagious, and Pete’s leadership style has proven tremendously effective.” More than twelve years ago, PharmaVOICE magazine established the PharmaVOICE 100. Selected from thousands of nominations, recipients are identified based on substantive accounts that illustrate how they have inspired or motivated their colleagues, peers, and competitors; have positively impacted their own organizations; and have contributed to their communities and other philanthropic causes. In 2014, PharmaVOICE magazine created the Red Jacket Award, their version of a “hall of fame” for PharmaVOICE 100 recipients who had been named to PharmaVOICE 100 multiple times. Recipients are individuals who challenge us to think, act and lead differently. True transformers of the life-sciences industry, they create new opportunities, have a persistence of vision and are inspired leaders. To view the complete PharmaVOICE Red Jacket Award profile for Herring, and/or the PharmaVOICE 100 profiles for Sirjuesingh and Marchesini, please visit the July/August 2017 online digital edition at pharmavoice.com/current-issue/?issue=214. Mission Pharmacal Company is a privately held pharmaceutical company based in San Antonio, Texas. For more than seven decades, the company has been improving the lives of people through every stage of life by identifying unmet healthcare needs and delivering innovative, high-quality prescription, over-the-counter, and dietary supplement products to meet these needs using only the purest ingredients and FDA-approved methods of manufacturing. Mission is recognized as a pioneer and leader in the therapeutic areas of women’s health and urology and also offers leading products through its pediatric, dermatology, primary care, and long-term care service lines. With the shared objective of improving the health of all moms and babies, Mission is proud to support the March of Dimes Foundation®, the leading nonprofit organization for pregnancy and baby health. Using an innovative business model, Mission created the Mission Family of Companies, a collection of wholly-owned subsidiaries including BioComp Pharma, Inc., a generic drug marketer; Alamo Pharma Services, Inc., a specialized contract sales organization; ProSolus, Inc., a transdermal drug developer and manufacturer; Espada Dermatology, Inc., a prescription and esthetic dermatology company; as well as BexR Logistix, LLC and their subsidiary company, EPIC Fulfillment, Inc., the logistics and fulfillment arms of the organization. Each company functions independently while their product and service offerings can be linked together to offer customizable solutions to a wide array of forward-thinking pharmaceutical and biotech companies. To learn more, please visit missionfamilyofcompanies.com. A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/414b566f-e1b1-4be7-8696-bcd42db5818a A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/eadb3226-dd8e-4d13-b186-9c66a3df4787


Patent
Mission Pharmacal Company and Laval University | Date: 2016-08-10

The present disclosure provides novel formulations suitable for the intravaginal delivery of tinidazole, as well as methods of using the same.


Now in its eighth year, partnership offers clear demonstration of Mission's commitment to families and stronger, healthier babies SAN ANTONIO, TX--(Marketwired - February 09, 2017) - Mission Pharmacal Company ("Mission") celebrated the kick off of its 2017 fundraising campaign in support of the March of Dimes Foundation®, and it's signature fundraiser March for Babies. The March of Dimes is committed to a world in which every baby gets a fighting chance. The company has been a national supporter of the March of Dimes since 2010 and during that time has contributed more than $2.1 million dollars to the organization through corporate sponsorship and fundraising efforts. March for Babies, one of the nation's favorite walking events, funds programs and research to address the health issues that threaten pregnant women and babies. This internal, employee-driven campaign is one element of the company's overall partnership with the March of Dimes. "There are many reasons Mission Pharmacal is continuing our partnership with MOD," states Mission Senior Vice President of Corporate Marketing Natalie Sirjuesingh. "First and foremost, we believe in March of Dimes' work to help every mother and baby. We believe that raising funds that help achieve their goals is simply the right thing to do. This is the eighth year of the partnership and I am proud of the commitment we've shown as a company and how our employees continue to rally to embrace and support the cause. It truly is an 'all hands on deck' effort for us -- from Mission owners and leadership team members, to the workers in our manufacturing plants, to the employees throughout all of the Mission Family of Companies." On a national level, any individual who raises $1,000 or more through March for Babies will be named a Champion for Babies. Mission employs many who have earned this notable distinction, and as a corporation Mission was the second highest ranked company in terms of 2016 March of Dimes fundraising throughout the San Antonio region. While most March for Babies fundraisers are set for April 29 and 30, events are held in nearly 500 communities nationwide. While Mission employees will participate in several cities, the company will have a more formalized presence at the San Antonio march on Saturday, May 13. That event will also serve as the culmination for the company's March for Babies fundraising campaign. Mission's involvement with the March of Dimes extends well beyond March for Babies support, however. Last year the company, makers of the CitraNatal® Family of prescription prenatal vitamins and Dr. Smith's® consumer baby line of products, served as Platinum Sponsor for the New Jersey and Georgia MOD Annual Nurse of the Year (NOTY) Awards events and sponsored two specific NOTY awards categories, Women's Health and Pediatrics. More than 380,000, or 1 in 10 babies, are born too soon in the United States each year. Preterm birth (birth before 37 weeks of pregnancy) is the number one killer of babies, and babies who survive early birth often face an increased risk of a lifetime of health challenges, such as breathing problems, cerebral palsy, intellectual disabilities, and more. In late 2016, the March of Dimes issued its annual Premature Birth Report Card, providing a look at how well the United States, each state, and counties in each state across the country are doing to reduce the serious problem of premature birth. For the first time in eight years, the rate of premature birth has gotten worse, driven by higher rates among specific racial and ethnic groups as well as geographic areas. The U.S. received a "C" grade on the report card, falling short of the organization's goal of reducing the preterm birth rate. "There are many parallels between our two organizations," says Sirjuesingh. "For more than 70 years Mission has pioneered innovative products, many of which were specifically formulated to meet the needs of women and babies. During almost that exact same timeframe, March of Dimes has continually supported research, education, vaccines, and breakthroughs that have helped improve the health of babies. It seems like a natural fit to have our two organizations work together for a common good." About the March of Dimes The March of Dimes is the leading nonprofit organization for pregnancy and baby health. For more than 75 years, moms and babies have benefited from March of Dimes research, education, vaccines, and breakthroughs. For the latest resources and health information, visit marchofdimes.org and nacersano.marchofdimes.org. To participate in our annual signature fundraising event, visit marchforbabies.org. If you have been affected by prematurity or birth defects, visit the shareourstory.org community to find comfort and support. For detailed national, state and local perinatal statistics, visit peristats.org. You can also find us on Facebook, Instagram, and Twitter. About Mission Pharmacal Company Mission Pharmacal Company is a privately held pharmaceutical company based in San Antonio, Texas. For more than seven decades, the company has been improving the lives of people through every stage of life by identifying unmet healthcare needs and delivering innovative, high-quality prescription, over-the-counter, and dietary supplement products to meet these needs using only the purest ingredients and FDA-approved methods of manufacturing. Mission is recognized as a pioneer and leader in the therapeutic areas of women's health and urology and also offers leading products through its pediatric, dermatology, primary care, and long-term care service lines. Using an innovative business model, Mission has created wholly-owned subsidiaries, BioComp Pharma, Inc., a generic drug marketer; Alamo Pharma Services, Inc., a specialized contract sales organization; ProSolus, Inc., a transdermal drug developer and manufacturer; Espada Dermatology, Inc., a consumer dermatology division; as well as BexR Logistix, LLC and their subsidiary company, EPIC Fulfillment, Inc., the logistics and fulfillment arms of Mission, to diversify its offerings and build forward-thinking partnerships with other pharmaceutical and biotech companies. Mission is proud to support the March of Dimes Foundation®, the leading nonprofit organization for pregnancy and baby health. To learn more, please visit missionpharmacal.com.


Patent
Mission Pharmacal Company | Date: 2015-02-11

A sprayable zinc oxide composition is provided. The sprayable zinc oxide composition can be used in the treatment of various skin conditions. The sprayable zinc oxide composition includes zinc oxide particles and a fluoro-olefin propellant. The present inventors have found that by selecting a propellant having a certain specific gravity, vapor pressure, and molecular weight, and by controlling the viscosity of the various components of the composition, the resulting zinc oxide composition resists settling such that a substantially homogeneous distribution of zinc oxide particles is maintained and can be evenly sprayed onto a surface without running once applied.


Patent
Mission Pharmacal Company | Date: 2015-02-11

A sprayable emulsion is provided. The emulsion can be used in the treatment of various skin conditions. The emulsion includes a hydrofluoro-based propellant, an emulsification system, an oil phase, a water phase, and active agent particles. Further, the emulsification system includes at least one nonionic emulsifier. The emulsion has a viscosity ranging from about 500 centipoise to about 10,000 centipoise and a hydrophilic to lipophilic balance (HLB) value of from about 2 to about 12. The present inventors have found that by selectively controlling the nature of the emulsification system and the viscosity of the emulsion, the active agent particles resist settling such that a substantially homogeneous distribution of the active agent particles is maintained and can be evenly sprayed onto a surface without running once applied.


Patent
Mission Pharmacal Company | Date: 2015-02-11

A spray delivery system including a sprayable active agent composition housed within a container is provided that can be used in the treatment of various skin conditions. The composition includes a hydrofluoro-based propellant, a carrier fluid, and active agent particles, and has a viscosity ranging from about 500 centipoise to about 10,000 centipoise. The container includes a dip tube; a valve assembly that includes a valve body, a stem comprising a stem orifice, and a vapor tap; and an actuator. The dip tube is coupled to the actuator by the valve assembly, and the actuator is depressed to dispense the emulsion. By selectively controlling the components and viscosity of the composition and the dimensions of the container components, the active agent particles resist settling so a substantially homogeneous distribution of the particles is maintained. Thus, the composition can be evenly dispensed from the container as a fine mist without clogging.


Patent
The University Of Texas and Mission Pharmacal Co. | Date: 2011-06-07

Small molecules and their derivatives are described for the treatment and/or prevention of intestinal fluid loss. Also disclosed are methods of using said molecules and their derivatives to treat and/or prevent conditions associated with increased levels of 3,5-adenosine monophosphate. Specific compositions of the invention are also novel.


Patent
Mission Pharmacal Company | Date: 2016-06-06

A sprayable emulsion is provided. The emulsion can be used in the treatment of various skin conditions. The emulsion includes a hydrofluoro-based propellant, an emulsification system, an oil phase, a water phase, and active agent particles. Further, the emulsification system includes at least one nonionic emulsifier. The emulsion has a viscosity ranging from about 500 centipoise to about 10,000 centipoise and a hydrophilic to lipophilic balance (HLB) value of from about 2 to about 12. The present inventors have found that by selectively controlling the nature of the emulsification system and the viscosity of the emulsion, the active agent particles resist settling such that a substantially homogeneous distribution of the active agent particles is maintained and can be evenly sprayed onto a surface without running once applied.


Patent
Laval University and Mission Pharmacal Company | Date: 2014-06-25

The present disclosure provides novel formulations suitable for the intravaginal delivery of tinidazole, as well as methods of using the same.


Patent
Mission Pharmacal Company | Date: 2010-01-04

Compounds are provided herein which are coordination complexes of the formula, A_(x)B_(y)Cit_(2)F_(z).mH_(2)O, wherein A is a cation selected from certain IA or IIA metal ions in the Periodic Table; B is a cation selected from certain IIA metal ions and certain divalent d-block transition metal ions; A and B are different; Cit is tribasic citric acid anion; the stoichiometric ratio of x to y is equal or higher than 1.0 but lower than 8.0; m is 0-12; and z is selected such that electroneutrality is preserved. Compounds provided herein are useful to treat dietary deficiencies, osteoporosis, osteopenia, bone loss, and risk of bone loss, as well as other medical conditions involving the need for administration of the various ions. In addition, the compounds can be used as fluoride sources for dental use and to fluoridate water systems.

Loading Mission Pharmacal Company collaborators
Loading Mission Pharmacal Company collaborators